Why the study?
Pulmonary hypertension increasingly affects older patients with complex comorbidities lacking adequate treatments, while the underlying endothelial pathophenotypes driving vasoconstriction and panvascular remodeling remain controversial and incompletely defined.
This review highlights endothelial senescence as a potential unifying mechanism and therapeutic target in pulmonary hypertension.
Endothelial senescence may be a therapeutic target in pulmonary hypertension; leaves open validation in prospective studies.
Pulmonary hypertension is an enigmatic, deleterious disease driven by multiple heterogeneous causes with a burgeoning proportion of older patients with complex, chronic comorbidities without adequate treatment options. The underlying endothelial pathophenotypes that direct vasoconstriction and panvascular remodeling remain both controversial and incompletely defined. This review discusses emerging concepts centered on endothelial senescence in pulmonary vascular disease. This principle proposes a more heterogeneous, dynamic pulmonary endothelium in disease; it provides a potentially unifying feature of endothelial dysfunction in pulmonary hypertension irrespective of cause; and it supports a clinically relevant link between aging and pulmonary hypertension like other chronic illnesses. Thus, taking cues from studies on aging and age-related diseases, we present possible opportunities and barriers to diagnostic and therapeutic targeting of senescence in pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Culley et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: